Scleroderma in children

Pediatric Clinics of North America

Volumn 52, Issue 2, 2005, Pages 521-545

  Zulian, Francesco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CALCIPOTRIOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; GLUCOCORTICOID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; PENICILLAMINE; PREDNISONE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PSORALEN; QUINAPRIL; RECOMBINANT GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL INFILTRATION; CELLULAR IMMUNITY; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG MEGADOSE; ECHOGRAPHY; FATALITY; HELPER CELL; HUMAN; INCIDENCE; JUVENILE; KIDNEY DISEASE; LABORATORY TEST; LOCALIZED SCLERODERMA; LUNG FIBROSIS; METASTASIS; MONONUCLEAR CELL; MORPHEA; NATURAL KILLER CELL; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PREMATURE OVARIAN FAILURE; PROGNOSIS; PULMONARY HYPERTENSION; PUVA; RACE DIFFERENCE; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SCLEROSIS; SKIN INDURATION; SYSTEMIC SCLEROSIS; VASCULAR DISEASE;

EID: 16244393727     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2005.02.001     Document Type: Review

References (149)

1. The American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Subcommittee for Scleroderma Criteria Preliminary criteria for the classification of systemic sclerosis (scleroderma) Arthritis Rheum 23 1980 581 590
2. Zulian F., Ruperto N., editors. Proceedings of the Second Workshop on Juvenile Scleroderma Syndrome. Padua, Italy, June 3-6, 2004
3. M.D. Mayes Scleroderma epidemiology Rheum Dis Clin North Am 29 2003 239 254
4. D.L. Tuffanelli, and R. LaPerriere Connective tissue diseases Pediatr Clin North Am 18 1971 925 951
5. H.K. Kornreich, K.K. King, and B.H. Bernstein Scleroderma in childhood Arthritis Rheum 20 1977 343 350
6. T.A. Medsger Jr Epidemiology of systemic sclerosis Clin Dermatol 12 1994 207 216
7. C.M. Black Scleroderma in children Adv Exp Med Biol 455 1999 35 48
8. G. Martini, I. Foeldvari, and R. Russo Systemic scleroderma syndromes in children: clinical and immunological characteristics of 181 patients Arthritis Rheum 48 9 2003 S512
9. S.A. Jimenez, and C.T. Derk Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis Ann Intern Med 140 2004 37 50
10. D.J. Abraham, X. Shiwen, and C.M. Black Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts J Biol Chem 275 2000 15220 15225
11. J. Varga, J. Rosenbloom, and S.A. Jimenez Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts Biochem J 247 1987 597 604
12. R. Stratton, X. Shiwen, and G. Martini Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients J Clin Invest 108 2001 241 250
13. E. Gore-Hyer, J. Pannu, and E.A. Smith Selective stimulation of collagen synthesis in the presence of costimulatory insulin signaling by connective tissue growth factor in scleroderma fibroblasts Arthritis Rheum 48 2003 798 806
14. B.W. Needleman, F.M. Wigley, and R.W. Stair Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma Arthritis Rheum 35 1992 67 72
15. M. Hasegawa, S. Sato, and H. Ihn Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis Rheumatology (Oxford) 38 1999 612 617
16. S.P. Atamas, V.V. Yurovsky, and R. Wise Production of type 2 cytokines by CD8 + lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis Arthritis Rheum 42 1999 1168 1178
17. S. Sato, H. Hanakawa, and M. Hasegawa Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis J Rheumatol 27 2000 2838 2842
18. M. Matucci-Cerinic, A. Pignone, and T. Lotti Reduced angiotensin converting enzyme plasma activity in scleroderma. A marker of endothelial injury? J Rheumatol 17 1990 328 330
19. M.B. Kahaleh, I. Osborn, and E.C. LeRoy Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon Ann Intern Med 94 1981 482 484
20. R. Sgonc, M.S. Gruschwitz, and H. Dietrich Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma J Clin Invest 98 1996 785 792
21. T. Ohtsuka, Y. Miyamoto, and A. Yamakage Quantitative analysis of microchimerism in systemic sclerosis skin tissue Arch Dermatol Res 293 2001 387 391
22. J.L. Nelson, D.E. Furst, and S. Maloney Microchimerism and HLA-compatible relationships of pregnancy in scleroderma Lancet 351 1998 559 562
23. C.M. Artlett, J.B. Smith, and S.A. Jimenez Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis N Engl J Med 338 1998 1186 1191
24. K.M. Goel, and R.A. Shanks Scleroderma in childhood. Report of 5 cases Arch Dis Child 49 1974 861 866
25. M.O. Jaffe, and R.K. Winkelmann Generalized scleroderma in children. Acrosclerotic type Arch Dermatol 83 1961 402
26. J.T. Cassidy, D.B. Sullivan, and L. Dabich Scleroderma in children Arthritis Rheum 20 1977 351 354
27. M.E. Suarez-Almazor, L.J. Catoggio, and J.A. Maldonado-Cocco Juvenile progressive systemic sclerosis: Clinical and serologic findings Arthritis Rheum 28 1985 699 702
28. V. Hanson Dermatomyositis, scleroderma, and polyarteritis nodosa Clin Rheumat Dis 2 1976 445
29. H.M. Lababidi, F.W. Nasr, and Z. Khatib Juvenile progressive systemic sclerosis: report of five cases J Rheumatol 18 1991 885 888
30. G. Spencer-Green, M. Schlesinger, and K.E. Bove Nailfold capillary abnormalities in childhood rheumatic diseases J Pediatr 102 1983 341 346
31. C.M. Duffy, R.M. Laxer, and P. Lee Raynaud syndrome in childhood J Pediatr 114 1989 73 78
32. T. Arkachaisri, T. Scalapini, and N. Fertig Comparison of clinical and serological findings in childhood and adult onset systemic sclerosis Arthritis Rheum 50 9 2004 S686 S687
33. W.A. D'Angelo, J.F. Fries, and A.T. Masi Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls Am J Med 46 1969 428 440
34. P. Weber, G. Ganser, and M. Frosch Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease J Rheumatol 27 2000 2692 2695
35. P. Quartier, D. Bonnet, and J.C. Fournet Severe cardiac involvement in children with systemic sclerosis and myositis J Rheumatol 29 2002 1767 1773
36. N.S. Eid, J.J. Buchino, and K.N. Schikler Pulmonary manifestations of rheumatic diseases Pediatr Pulmonol Suppl 18 1999 91 92
37. D.M. Koh, and D.M. Hansell Computed tomography of diffuse interstitial lung disease in children Clin Radiol 55 2000 659 667
38. J.M. Seely, L.T. Jones, and C. Wallace Systemic sclerosis: using high-resolution CT to detect lung disease in children Am J Roentgenol 170 3 1998 691 697
39. P. Lee, J. Bruni, and S. Sukenik Neurological manifestations in systemic sclerosis (scleroderma) J Rheumatol 11 1984 480 483
40. S. Sato, Y. Hamaguchi, and M. Hasegawa Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis Rheumatology (Oxford) 40 2001 1135 1140
41. V.D. Steen, J.K. Lanz Jr, and C. Conte Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study Arthritis Rheum 37 1994 1290 1296
42. F.H. van den Hoogen, A.M. Boerbooms, and A.J. Swaak Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial Br J Rheumatol 35 1996 364 372
43. J.E. Pope, N. Bellamy, and J.R. Seibold A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma Arthritis Rheum 44 2001 1351 1358
44. R.J. Stratton, H. Wilson, and C.M. Black Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma Rheumatology (Oxford) 40 2001 84 88
45. P.J. Clements, D.E. Furst, and D.S. Campion Muscle disease in progressive systemic sclerosis: Diagnostic and therapeutic considerations Arthritis Rheum 21 1978 62 71
46. V.D. Steen, and T.A. Medsger Jr Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis Arthritis Rheum 41 1998 1613 1619
47. M.H. Ellman, P.A. MacDonald, and F.A. Hayes Etanercept as treatment for diffuse scleroderma: a pilot study [abstract] Arthritis Rheum 43 2000 S392
48. N.M. Wulffraat, L.A. Sanders, and W. Kuis Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease Curr Rheumatol Rep 2 2000 316 323
49. M. Binks, J.R. Passweg, and D. Furst Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease Ann Rheum Dis 60 2001 577 584
50. D. Farge, J. Passweg, and J. van Laar Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry Ann Rheum Dis 63 8 2004 974 981
51. M.I.V. Jayson, C. Lovell, and C.M. Black Penicillamine therapy in systemic sclerosis Proc R Soc Med 70 Suppl 3 1977 82 88
52. V.D. Steen, T.A. Medsger Jr, and G.P. Rodnan D-penicillamine therapy in progressive systemic sclerosis: a retrospective analysis Ann Intern Med 97 1982 652 659
53. S.A. Jimenez, and S.H. Sigal A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine J Rheumatol 18 1991 1496 1503
54. P.J. Clements, D.E. Furst, and W.K. Wong High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double blind, randomized, controlled clinical trial Arthritis Rheum 42 1999 1194 1203
55. C.D. Smith, and R.J. McKendry Controlled trial of nifedipine in the treatment of Raynaud's phenomenon Lancet 2 1982 1299 1301
56. R.J. Rodeheffer, J.A. Rommer, and F. Wigley Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon N Engl J Med 308 1983 880 883
57. J. Sauza, A. Kraus, and R. Gonzalez-Amaro Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial J Rheumatol 11 1984 362 364
58. F. Zulian, F. Corona, and V. Gerloni Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases Rheumatology (Oxford) 43 2004 229 233
59. C.M. Black, L. Halkier-Sorensen, and J.J. Belch Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study Br J Rheumatol 37 1998 952 960
60. F.M. Wigley, J.H. Korn, and M.E. Csuka Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study Arthritis Rheum 41 1998 670 677
61. V.L. Beckett, J.V. Donadio Jr, and L.A. Brennan Jr Use of captopril as early therapy for renal scleroderma: a prospective study Mayo Clin Proc 60 1985 763 771
62. V.D. Steen, J.P. Costantino, and A.P. Shapiro Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors Ann Intern Med 113 1990 352 357
63. P. Moddison Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition Rheumatology (Oxford) 41 2002 965 971
64. B. White, W.C. Moore, and F.M. Wigley Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis Ann Intern Med 132 2000 947 954
65. K.P. Kuhn, D.W. Byrne, and P.G. Arbogast Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol Am J Respir Crit Care Med 167 2003 580 586
66. D.B. Badesch, V.F. Tapson, and M.D. McGoon Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial Ann Intern Med 132 2000 425 434
67. L.J. Rubin, D.B. Badesch, and R.J. Barst Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
68. C.R. Bottoni, K.A. Reinker, and R.D. Gardner Scleroderma in childhood: a 35-year history of cases and review of the literature J Pediatr Orthop 20 2000 442 449
69. I. Foeldvari, M. Zhavania, and N. Birdi Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey Rheumatology (Oxford) 39 2000 556 559
70. S. Jacobsen, P. Halberg, and S. Ullman Mortality and causes of death of 344 Danish patients with systemic sclerosis Br J Rheumatol 37 1998 750 755
71. L.S. Peterson, A.M. Nelson, and W.P.D. Su Subspecialty clinics: rheumatology and dermatology. Classification of morphea (localized scleroderma) Mayo Clin Proc 70 1995 1068 1076
72. C. Bodemer, and M. Belon Scleroderma in children: a retrospective study of 70 cases Ann Dermatol Venereol 126 1999 691 694
73. L.S. Peterson, A.M. Nelson, and W.P. Su The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993 J Rheumatol 24 1997 73 80
74. J.E. Levinson, and K.E. Bove Scleroderma M.E. Gershwin D.E. Robbins Musculoskeletal diseases of children 1983 Grune & Stratton Orlando (FL) 195 208
75. U.F. Haustein, and B. Haupt Drug-induced scleroderma and sclerodermiform conditions Clin Dermatol 16 1998 353 366
76. E. Aberer, R. Neumann, and G. Stanek Is localised scleroderma a Borrelia infection? Lancet 2 1985 278
77. W. Fan, C.L. Leonardi, and N.S. Penneys Absence of Borrelia burgdorferi in patients with localized scleroderma (morphea) J Am Acad Dermatol 33 1995 682 684
78. R. Vancheeswaran, C.M. Black, and J. David Childhood onset scleroderma: is it different from adult onset disease? Arthritis Rheum 39 1996 1041 1049
79. V. Falanga, T.A. Medsger, and M. Reichlin Linear scleroderma: clinical spectrum, prognosis and laboratory abnormalities Ann Intern Med 104 1986 849 857
80. M.H. Kanzler, D.C. Gorsulowsky, and N.A. Swanson Basic mechanisms in the healing of cutaneous wound J Dermatol Surg Oncol 12 1986 1156 1164
81. F. Zulian, S.K.F. De Oliveira, and T.H. Lehman Juvenile localized scleroderma: clinical epidemiological features of 688 patients [abstract] Arthritis Rheum 48 9 2003 512
82. M.S. Daoud, W.P. Su, and K.M. Leiferman Bullous morphea: clinical, pathologic, and immunopathologic evaluation of thirteen cases J Am Acad Dermatol 30 1994 937 943
83. S. Menni, A.V. Marzano, and E. Passoni Neurologic abnormalities in two patients with facial hemiathrophy and sclerosis coexisting with morphea Pediatr Dermatol 14 1997 113 116
84. M. Blaszczyk, and S. Jablonska Linear scleroderma en coup de sabre: relationship with progressive facial hemiatrophy Adv Exp Med Biol 455 1999 101 104
85. T.J. Lehman The Parry Romberg syndrome of progressive facial herniathrophy and linear scleroderma en cop de sabre: mistaken diagnosis or overlapping conditions? J Rheumatol 19 1992 844 845
86. J.R. Person, and W.P. Su Subcutaneous morphoea: a clinical study of sixteen cases Br J Dermatol 100 1979 371 380
87. W.P. Su, and J.R. Person Morphea profunda: a new concept and a histopathologic study of 23 cases Am J Dermatopathol 3 1981 251 260
88. S.J. Whittaker, N.P. Smith, and R.R. Jones Solitary morphoea profunda Br J Dermatol 120 1989 431 440
89. J.L. Diaz-Perez, S.M. Connolly, and R.K. Winkelmann Disabling pansclerotic morphea in children Arch Dermatol 116 1980 169 173
90. L.E. Shulman Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians 88 1975 70 86
91. G.P. Rodnan, A. Di Bartolomeo, and T.A. Medsgar Jr Eosinophilic fasciitis. Report of six cases of a newly recognized scleroderma-like syndrome Arthritis Rheum 18 1975 525
92. J.J. Miller III The fasciitis-morphea complex in children Am J Dis Child 146 1992 733 736
93. C. Lunderschmidt, G. König, and B. Leisner Zirkumskripte sklerodermie: interne manifestationen und signifikante correlation zu HLA-DR1 und -DR5 Hautarzt 36 1985 516 521
94. L. Dehen, J.C. Roujeau, and A. Cosnes Internal involvement in localized scleroderma Medicine 73 1994 241 245
95. F. Zulian, R. Russo, and R. Laxer Is juvenile localized scleroderma really "localized"? [abstract] Arthritis Rheum 48 9 2003 512
96. E. Heron, A. Hernigou, and P. Fornes Central nervous system involvement in scleroderma Ann Med Interne (Paris) 153 3 2002 179 182
97. M. Blaszczyk, L. Krolicki, and M. Krasu Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre J Rheumatol 30 2003 1997 2004
98. S. Grosso, A. Fioravanti, and G. Biasi Linear scleroderma associated with progressive brain atrophy Brain Dev 25 2003 57 61
99. A.R. Woolfenden, D.C. Tong, and A.M. Norbash Progressive facial hemiatrophy: abnormality of intracranial vasculature Neurology 50 6 1998 1915 1917
100. J. David, J. Wilson, and P. Woo Scleroderma "en coup de saber" Ann Rheum Dis 50 1991 260 262
101. H. Goldberg-Stern, T. deGrauw, and M. Passo Parry-Romberg syndrome: follow-up imaging during suppressive therapy Neuroradiology 39 12 1997 873 876
102. D.E. Flores-Alvarado, J.A. Esquivel-Valerio, and M. Garza-Elizondo Linear scleroderma en coup de sabre and brain calcifications: is there a pathogenic relationship? J Rheumatol 30 2003 193 195
103. Y. Higashi, T. Kanekura, and K. Fukumaru Scleroderma en coup de sabre with central nervous system involvement J Dermatol 27 7 2000 486 488
104. W. Luer, D. Jockel, and T. Henze Progressive inflammatory lesions of the brain parenchyma in localized scleroderma of the head J Neurol 237 1990 379 381
105. A.I. Miedziak, M. Stefanyszyn, and J. Flamagan Parry-Romberg syndrome associated with intracranial vascular malformations Arch Ophthalmol 116 1998 1235 1237
106. C. Goldenstein-Schainberg, R.M. Pereira, and M.C. Gusukuma Childhood linear scleroderma "en coup de sabre" with uveitis J Pediatr 117 1990 581 584
107. J. Serup, and P.H. Alsbirk Localized scleroderma "en coup de sabre" and iridopalpebral atrophy at the same line Acta Derm Venereol 63 1983 75 77
108. W.W. Campbell, and F.J. Bajandas Restrictive ophthalmopathy associated with linear scleroderma J Neuroophthalmol 15 1995 95 97
109. R.A. Tang, L. Mewis-Christmann, and J. Wolf Pseudo-oculomotor palsy as the presenting sign of linear scleroderma J Pediatr Ophthalmol Strabismus 23 1986 236 238
110. M.S. Suttorp-Schulten, and L. Koornneef Linear scleroderma associated with ptosis and motility disorders Br J Ophthalmol 74 1990 694 695
111. G. Zaninotto, A. Peserico, and M. Costantini Oesophageal motility and lower oesophageal sphincter competence in progressive systemic sclerosis and localized scleroderma Scand J Gastroenterol 24 1989 95 102
112. P. Weber, G. Ganser, and M. Frosh Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease J Rheumatol 27 2000 2692 2695
113. C. Bourgeois-Droin, and R. Touraine Sclérodermie en plaque: Perturbations immunologique et viscérales Ann Med Interne (Paris) 129 1978 107 112
114. N. Birdi, R.M. Laxer, and P. Thorner Localized scleroderma progressing to systemic disease. Case report and review of the literature Arthritis Rheum 36 1993 410 415
115. F.J. Mayorquin, T.L. McCurley, and J.E. Levernier Progression of childhood linear scleroderma to fatal systemic sclerosis J Rheumatol 21 1994 1955 1957
116. H.B. Christianson, C.S. Dorsey, and P.A. O'Leary Localized scleroderma. A clinical study of two hundred thirty-five cases Arch Dermatol 74 1956 629 639
117. H.K. Kornreich, K.K. King, and B.H. Bernstein Scleroderma in childhood Arthritis Rheum 20 Suppl 2 1977 343 350
118. E. Torok, and E. Ablonczy Morphoea in children Clin Exp Dermatol 11 1986 607 612
119. Y. Uziel, B.R. Krafchik, and E.D. Silverman Localized scleroderma in childhood: a report of 30 cases Semin Arthritis Rheum 23 1994 328 340
120. K. Takehara, Y. Moroi, and Y. Nakabayashi Antinuclear antibodies in localized scleroderma Arthritis Rheum 26 1983 612 616
121. M. Blaszczyk, M. Jarzabek-Chorleska, and S. Jablonska Relationship between cutaneous and systemic scleroderma. Are immunopathological studies helpful in evaluating transition of cutaneous to systemic scleroderma? Przegl Dermatol 2 2000 119 125
122. A.V. Marzano, and S. Menni Localized scleroderma in adults and children. Clinical and laborator investigations on 239 cases Eur J Dermatol 13 2003 171 176
123. S. Sato, M. Fujimoto, and M. Hasegawa Antiphospholipid antibody in localized scleroderma Ann Rheum Dis 62 2003 771 774
124. Y. Uziel, B.R. Krafchik, and B. Feldman Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma Arthritis Rheum 37 1994 898 901
125. G. Martini, K.J. Murray, and K.J. Howell Juvenile-onset localized scleroderma activity detection by infrared thermography Rheumatology (Oxford) 41 10 2002 1178 1182
126. N. Birdi, A. Shore, and P. Rush Childhood linear scleroderma: a possible role of thermography for evaluation J Rheumatol 19 1992 968 973
127. P. Liu, Y. Uziel, and S. Chuang Localized scleroderma: imaging features Pediatr Radiol 24 1994 207 209
128. S. Seidenari, A. Conti, and P. Pepe Quantitative description of echographic images of morphea plaques as assessed by computerized image analysis on 20 MHz B-scan recordings Acta Derm Venereol 75 1995 442 445
129. A. Cosnes, M.C. Anglade, and J. Revux Thirteen-megahertz ultrasound probe: its role in diagnosing localized scleroderma Br J Dermatol 148 2003 724 729
130. E.M. Chazen, C.D. Cook, and J. Cohen Focal scleroderma J Pediatr 60 1962 385 393
131. B.B. Cunningham, I.D. Landells, and C. Langman Topical calcipotriene for morphea/linear scleroderma J Am Acad Dermatol 39 1998 211 215
132. Y. Uziel, B.M. Feldman, B.R. Krafchik, R.S. Yeung, and R.H. Laxer Methotrexate and corticosteroid therapy for pediatric localized scleroderma J Pediatr 136 2000 91 95
133. J. Walsh, G. Martini, and K.J. Murray Evaluation and treatment of childhood onset localized scleroderma [abstract] Arthritis Rheum 42 9 1999 231
134. J.E. Pope, N. Bellamy, and J.R. Seibold A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma Arthritis Rheum 44 6 2001 1351 1358
135. C.M. Herbert, K.A. Lindberg, and M.I.V. Jayson Biosynthesis and maturation of skin collagen in scleroderma and effect of D-penicillamine Lancet 1 1974 187 192
136. J. Uitto, P. Helin, and O. Rasmussen Skin collagen in patients with scleroderma: biosynthesis and maturation in vitro, and the effect of D-penicillamine Ann Clin Res 2 1970 228 234
137. V. Falanga, and T.A. Medsger Jr D-penicillamine in the treatment of localised scleroderma Arch Dermatol 126 1990 609 612
138. N. Hunzelmann, S. Anders, and G. Fierlbeck Double-blind, placebo-controlled study of intra-lesional interferon gamma for the treatment of localized scleroderma J Am Acad Dermatol 36 3 Pt 1 1997 433 435
139. M.A. De Rie, and J.D. Bos Photochemotherapy for systemic and localized scleroderma J Am Acad Dermatol 43 2000 725 726
140. M. Kerscher, M. Volkenandt, and C. Gruss Low dose UVA phototherapy for treatment of localized scleroderma J Am Acad Dermatol 38 1998 21 26
141. N.R. Camacho, J.E. Sanchez, and R.F. Martin Medium dose UVA phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells J Am Acad Dermatol 45 2001 697 699
142. B. Cribier, T. Faradij, and C. Le Coz Extracorporeal photochemotherapy in systemic sclerosis and severe morphea Dermatology 191 1995 25 31
143. M. Grundmann-Kollmann, F. Ochsendorf, and T.M. Zollner PUVA cream photochemotherapy for the treatment of localized scleroderma J Am Acad Dermatol 43 2000 675 678
144. N.G. Caca-Biljanovska, M.T. Vlckova-Laskoska, and D.V. Dervendi Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3 Adv Exp Med Biol 455 1999 299 304
145. B.B. Cunningham, I.D. Landells, and C. Langman Topical calcipotriene for morphea/linear scleroderma J Am Acad Dermatol 39 2 Pt 1 1998 211 215
146. M.M. Hulshof, S. Pavel, and F.C. Breedveld Oral calcitriol as a new therapeutic modality for generalized morphea Arch Dermatol 130 1994 1290 1293
147. M.M. Hulshof, B.J.N. Bouwes, and W. Bergman Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized scleroderma and systemic scleroderma J Am Acad Dermatol 43 2000 1017 1023
148. M. Sengezer, M. Deveci, and N. Selmanpakoglu Repair of "coup de sabre," a linear form of scleroderma Ann Plast Surg 37 1996 428 432
149. J. Lapiere, S. Aasi, and B. Cook Successful correction of depressed scars of the forehead secondary to trauma and morphea en coup do sabre by en bloc autologous dermal fat graft Dermatol Surg 26 2000 793 797